# AGN-229666 for the Treatment of Allergic Conjunctivitis

> **NCT01754766** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 90 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** AGN-229666
- **OTHER:** vehicle of AGN-229666

## Key facts

- **NCT ID:** NCT01754766
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-01
- **Final completion:** 2013-02
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01754766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01754766, "AGN-229666 for the Treatment of Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01754766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*